EphA2 has emerged as a significant target in various solid tumours, as its role in tumour angiogenesis, cell migration, and survival contributes to its oncogenic potential74 and many studies have explored the targeting of EphA2‐CAR T cells against a variety of solid tumours, including preclinical models of OS and EWS.83, 84. This evidence concerns the gene EPHA2 and neoplasm.